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Well-known effects of neurotrophic factors are related to supporting the survival and
functioning of various neuronal populations in the body. However, these proteins seem
to also play less well-documented roles in glial cells, thus, influencing neuroinflammation.
This article summarizes available data on the effects of glial cell line derived neurotrophic
factor (GDNF) family ligands (GFLs), proteins providing trophic support to dopaminergic,
sensory, motor and many other neuronal populations, in non-neuronal cells contributing
to the development and maintenance of neuropathic pain. The paper also contains our
own limited data describing the effects of small molecules targeting GFL receptors on the
expression of the satellite glial marker IBA1 in dorsal root ganglia of rats with surgery- and
diabetes-induced neuropathy. In our experiments activation of GFLs receptors with either
GFLs or small molecule agonists downregulated the expression of IBA1 in this tissue
of experimental animals. While it can be a secondary effect due to a supportive role
of GFLs in neuronal cells, growing body of evidence indicates that GFL receptors are
expressed in glial and peripheral immune system cells. Thus, targeting GFL receptors
with either proteins or small molecules may directly suppress the activation of glial and
immune system cells and, therefore, reduce neuroinflammation. As neuroinflammation
is considered to be an important contributor to the process of neurodegeneration these
data further support research efforts to modulate the activity of GFL receptors in order to
develop disease-modifying treatments for neurodegenerative disorders and neuropathic
pain that target both neuronal and glial cells.
Keywords: neurotrophic factors, glial cell line-derived neurotrophic factor (GDNF), GDNF family ligands, receptor
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INTRODUCTION
Neurotrophic factors (NTFs) support the development, survival, and functioning of different
neuronal populations via activation of intracellular signaling cascades important for well-being
of the cells. Currently four families of proteins are being referred to as NTFs: neurotrophins,
neurokines, glial cell line-derived neurotrophic factor (GDNF) family ligands (GFLs), and
cerebral dopamine neurotrophic factor (CDNF)/mesencephalic astrocyte-derived neurotrophic
factor (MANF). Members of the first three families of NTFs signal via transmembrane kinase or
kinase-associated receptors (Sidorova and Saarma, 2016; Sidorova et al., 2019). The mechanism
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of CDNF/MANF signaling is less well-studied, they are
endoplasmic reticulum associated proteins and may interact
with lipids. Some studies suggest that the entry of CDNF and
MANF into the cell as well as their biological effects can
be mediated by lipids (Bai et al., 2018). Recent study also
showed that transmembrane protein neuroplastin, belonging to
immunoglobulin superfamily, may serve as a receptor for MANF
and mediate anti-inflammatory effects of this NTF (Yagi et al.,
2020).
Although the effects of NTFs were originally evaluated in
neuronal cells, growing body of evidence indicates that they may
also influence glial cells and modulate neuroinflammation. In the
current review we will focus mainly on the role of GFLs and their
receptors in sensory neurons and glial cells in neuropathic pain,
but also mention some other NTFs.
Neurotrophins, neurokines and GFLs have been extensively
studied in sensory system and in neuropathic pain (Khan and
Smith, 2015; Eapen et al., 2019; Mahato and Sidorova, 2020a).
According to a definition given by International Association
of the Study of Pain (IASP) neuropathic pain is a “pain caused
by a lesion or disease of the somatosensory nervous system”
(Murnion, 2018). Current view on pathogenesis of neuropathic
pain implies the interplay of several cell types including at least
sensory neurons, glial cells, peripheral immune cells and target-
derived cells. Nerve lesion activates glial and immune cells which
start to secrete various proinflamatory cytokines, growth factors
and other inflammatorymediators which sensitize peripheral and
central neurons (Ji X.-T. et al., 2013).
The role of neurotrophins and neurokines in
neuroinflammation is well-established (Davis et al., 2018;
Lima Giacobbo et al., 2019; Parker et al., 2019; Hu et al., 2020;
Yin et al., 2020). These proteins are also mainly pronociceptive
although some of them can have antinociceptive effects
as well (Khan and Smith, 2015; Hu et al., 2020). A good
summary of neurotrophins’ actions in the sensory system
can be found in the review of Khan and Smith (2015).
According to the available information CDNF and MANF
suppress neuroinflammation (Nadella et al., 2014; Zhang
et al., 2019) and may promote nerve regeneration (Lindholm
et al., 2007; Zhao et al., 2016) and repair lesioned tissues
(Neves et al., 2016; Tseng et al., 2018; Eesmaa et al., 2021),
however, their effects in sensory system at the moment are
poorly documented. Anti-inflammatory effects of MANF in
human beta cells are mediated by downregulation of cytokine
expression (IL-1b and TNF-a) (Hakonen et al., 2018). In a model
of traumatic brain injury MANF also suppressed expression
of proinflammatory cytokines and reduced the disruption of
blood brain barrier. On molecular level MANF downregulated
NF-κB signal transduction pathway (Li et al., 2018). Since these
mechanisms are rather universal for inflammatory responses
in the body further studies on the effects of MANF and
CDNF in somatosensory system in neuropathic pain models
are warranted.
Scientific literature on biological effects of GFLs in
neuropathic pain contains variable data (Sah et al., 2005;
Ossipov, 2011; Merighi, 2016; Ferrini et al., 2020, Cortés et al.,
2017). While in rats in injury-based models of neuropathic
pain these proteins seem to exert mainly analgesic effects,
in inflammatory pain models and in mice they often induce
hyperalgesia and/or allodynia. Administration schedule and
duration of the treatment with GFL also seem to influence
the outcome (Mahato and Sidorova, 2020a). In recent clinical
trials in patients with neuropathic pain one of GFLs, artemin
(ARTN, also known as enovin and neublastin), was found
to be safe and relatively well-tolerated (Rolan et al., 2015;
Okkerse et al., 2016). Moreover, it exhibited analgesic effects
in a cohort of patients with neuropathic pain resistant to
the treatment with standard analgesics (Backonja et al.,
2017).
While the main mechanism of GFLs effects in neuropathic
pain is considered to appear as a result of trophic support
and neurorestoration in somatosensory system, these proteins
may also modulate neuroinflammation. This effect can be
secondary and appear as a result of restoration of injured
sensory neurons, which in turn reduces neuroinflammation,
but can also be mediated by a direct action of GFLs
in glial cells. In the present review we at first will list
the cell types playing a role in neuropathic pain and
depict their interactions. Afterwards we will discuss the
effects of GFLs in neuronal and non-neuronal cells in
somatosensory system. We will also describe the expression
of GFLs receptors in various cell types in somatosensory
system and present own data showing downregulation of
satellite glial marker in dorsal root ganglia (DRGs) upon
treatment with GFLs or GFL receptors agonists in animals with
experimental neuropathies.
CELL TYPES PLAYING A ROLE IN
NEUROPATHIC PAIN
In early studies, neuropathic pain was associated exclusively
with neuronal dysfunction (Zhuo, 2007). Therefore, the first-
line treatments for neuropathic pain are mainly aimed at
reducing the excitability of neurons by modulating the activity
of ion channels (gabapentinoids) or enhancing endogenous
inhibitory mechanisms (tricyclic antidepressants and serotonin-
noradrenaline reuptake inhibitors) (Attal and Bouhassira, 2015;
Finnerup et al., 2015).
In general in acute and neuropathic pain signal from
nociceptors does not immediately damage neurons, the
nociceptors thresholds are lower than the stimulus intensity
needed to damaged tissues, and, once activated, they
release a cocktail of fast-acting (glutamate) and slow-acting
neurotransmitters (peptides, trophic factors) from their central
terminals (Merighi, 2016).
In the concept of neuronal dysfunction NMDA receptors,
which play a critical role in synaptic plasticity in pain
transmission pathways may represent a key component.
However, in practice, targeting NMDA receptors turned out
to be complicated. Non-selective NMDA antagonists produce
a number of side effects that limit their clinical use and
contribute to treatment failure (Aiyer et al., 2018). NMDA
receptor antagonists selective for the N-methyl D-aspartate
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receptor subtype 2B (NR2B) (Kim et al., 2012) produce less
adverse events (Wu and Zhuo, 2009; Zhang et al., 2009), but their
efficacy remains to be improved (Boyce et al., 1999; Dahanl et al.,
2011; Swartjes et al., 2011).
Although the pathophysiology of neuropathic pain is still
controversial, an important step forward in understanding its
mechanisms was the realization that neurons are not the only
cell type involved in the etiology of this condition. Macrophages,
satellite glial cells, microglia and astrocytes, all these non-
neuronal cells produce both pro-nociceptive and anti-nociceptive
mediators (see Figure 1), which can bind their respective
receptors in the nociceptor neurons and modulate their
sensitivity and excitability, thus mediating pain transmission in
the PNS and CNS.
Macrophages have different phenotypes related to their
functional status, including pro-inflammatory M1-like and anti-
inflammatory M2-like phenotypes (Martinez and Gordon, 2014).
These cells are involved in modulation of pain through the
release of pro-inflammatory (such as TNF and IL-1β) or anti-
inflammatory mediators (such as IL-10) (Ji et al., 2016).
Satellite glial cells (SGCs) are the main type of homeostatic
glial cells in PNS ganglia (sensory, parasympathetic and
sympathetic). SGCs are functionally similar to astrocytes (Jasmin
et al., 2010). In animal model of intervertebral foraminal stenosis
and low-back pain, chronic compression of the DRGs led to
an enhancement of glial fibrillary acidic protein expression in
SGCs (in the absence of hypertrophy and proliferation usually
occurring after sciatic nerve axotomy), an increase in SGCs
coupling via gap junctions and a decrease in inwardly rectifying
potassium currents. These events were accompanied by increased
excitability of DRG neurons. Based on collected data the authors
suggested that altered potassium balance in SGCs may lead
to the neuronal hyperexcitability (Zhang et al., 2009). SGCs
similarly to astrocytes in CNS scavenge extracellular glutamate,
however, the increase in the number of gap junctions leads to
glutamate recycling thus contributing to the development and/or
maintenance of neuropathic pain (Ohara et al., 2008; Jasmin et al.,
2010).
Microglial cells are among the key players in the development
of neuropathic pain (Block et al., 2007; Suter et al., 2007; Beggs
et al., 2012).
Microglia in response to any damage or other abnormal
situation in the nervous system initiates an inflammatory
response. Due to the presence of immune receptors such as
toll-like receptors (TLRs), nucleotide-binding oligomerization
domains (NODs), NOD-like receptors, and many scavenger
receptors microglial cells (as well as some other cells in
the nervous system, e.g., astrocytes) are able to recognize
pathological stimuli (Ransohoff and Brown, 2012). In response
to these stimuli, microglia releases inflammatory mediators such
as tumor necrosis factor (TNF)-α, interleukin (IL)-1, IL-6 and
IL-12, interferon-γ (IFNγ) and generates reactive oxygen and
nitrogen species (Block et al., 2007; Colton and Wilcock, 2010;
Guzman-Martinez et al., 2019), which produce a long-lasting
sensory neuron hypersensitivity.
After peripheral nerve injury, molecules released from
the spinal cord neurons contribute to spinal microglial
activation, causing proliferation and changes in morphology.
The key molecule that modulates microglial activity is ATP,
an endogenous ligand of the P2 purinergic receptor family.
Microglia expresses several subtypes of P2 receptor, and of
these, the P2X4 has become the main cross-signaling junction
point between microglia and neurons: activation of this receptor
stimulates the release of trophic factors and other signaling
mediators which in turn trigger neuronal processes such as pain
signaling disinhibition (Trang et al., 2011; Ji et al., 2016; Tsuda
and Inoue, 2016) and/or neurorestoration.
Importance of microglia in the development of neuropathic
pain is also highlighted in the research article of Tsuda et al.,
where the authors showed that näive spinal microglia of
experimental animals expresses a receptor for the cytokine IFN-
γ (IFN-γR) in a cell-type-specific manner. Stimulation of this
receptor converts resting microglia into activated form and
produces a long-lasting hypersensitivity in response to innocuous
stimuli (tactile allodynia, a hallmark symptom of neuropathic
pain). Conversely, ablating IFN-γR severely impairs nerve
injury-evoked microglia activation and tactile allodynia without
affecting microglia in the contralateral dorsal horn. At the same
time, basal pain sensitivity remains unaffected. The authors
also demonstrated an up-regulation of Lyn tyrosine kinase and
purinergic P2X4 receptor in IFN-γ-stimulated spinal microglia
which are crucial events for neuropathic pain development
(Tsuda et al., 2009).
Important role in activation of glial cells in neuropathic
pain belongs to BDNF (Ferrini and De Koninck, 2013).
Spinal microglia in response to peripheral nerve injury
upregulates expression of P2X4 receptors. Activation of
P2X4 receptors initiates a signaling cascade which leads to
BDNF release which causes aberrant nociceptive output that
underlies pain hypersensitivity characterized by hyperalgesia,
allodynia, and spontaneous pain (Trang et al., 2011). BDNF
produced by microglia forms a positive feedback loop and
acts as an autocrine microglia stimulator (Zhang et al., 2014).
Also, in experimental morphine-induced hyperalgesia model
morphine caused upregulation of P2X4Rs in the spinal cord
microglia, driving synthesis and release of BDNF (Ferrini et al.,
2013).
In addition, BDNF activates astrocytes which may sensitize
the nociceptive pathway through the release of pro-inflammatory
factors, such as cytokines, prostaglandins, or neurotrophins,
which in turn contributes to neuropathic pain development
(Zhang et al., 2011).
Microglia also interacts with astrocytes after sensory nerve
injury. Wang et al. (2017) showed that tetanic stimulation
of sciatic nerve induces sciatic nerve injury and long-lasting
hypersensitivity in rats. In this model IL-18 was released
from activated microglia and together with chemokine CX3CL1
activated NF-kB pathway in astrocytes via IL18R and CX3C1R,
respectively which resulted in upregulation of the expression
of pro-inflammatory cytokines (Wang et al., 2017). In addition
astrocyte-derived IL-1β and IL-23 are thought to promote
allodynia/behavioral sensitization to nociceptive stimulation, by
modulating NMDA receptor activities in post-synaptic neurons
(Bian et al., 2014).
Astrocytes perform numerous critical functions in the
nervous system including, amongmany others, neurotransmitter
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FIGURE 1 | Interaction between nociceptors and different non-neuronal cells. ATP, Adenosine triphosphate; BDNF, Brain derived neurotrophic factor; Glu, glutamate;
IL-1β, Interleukin 1 β; IL-10, Interleukin 10; M1, pro-inflammatory phenotype; M2, anti-inflammatory phenotype; TGF-α, Transforming growth factor α; TNF-α, Tumor
necrosis factor α.
recycling, formation of the blood-brain barrier, regulation
of extracellular ion concentrations, and modulation of
synaptic transmission.
After nerve injury, astrocytes lose their ability to maintain
the homeostatic concentrations of extracellular potassium ions
and glutamate, which leads to neuronal hyperexcitability
(Ji R.-R. et al., 2013). Astrocytes can also signal directly to
neurons through physically coupled networks mediated by gap
junctions which facilitate intercellular signal transmission. Gap
junction communication is mediated by connexin-43 (Cx43),
the predominant connexin expressed in astrocytes. Nerve injury
induces persistent up-regulation of Cx43 in astrocytes and
switches the function of Cx43 from gap junction communication
to paracrine modulation (Chen et al., 2014). This paracrine
regulation leads to the increased release of glutamate, ATP, and
chemokines by astrocytes. The astrocyte-derived chemokines
act as neuromodulators and can potentiate excitatory synaptic
transmission in the spinal cord pain circuitry.
A single human astrocyte may form contacts with more than
1 million synapses (Oberheim et al., 2009). The complexity of
the connections points to an important role of astrocytes in
nervous system that bears further investigation. As compared
with microglial activation, astrocyte activation in chronic
pain conditions is more persistent and usually occurs later
than microglial activation, indicating their contribution to the
chronification of pain (Ji R.-R. et al., 2013).
Liu et al. (2020) in a recent review described interactions
of microglia and astrocytes in the neurovascular unit using
the concept of phenotypic switch between pro-inflammatory
(M1 and A1, respectively) and anti-inflammatory (M2 and A2,
respectively) phenotypes.
The most-discussed current classification of
microglia/macrophages is based on the M1/M2 paradigm,
which is related to their pro- and anti-inflammatory properties
(Martinez and Gordon, 2014). The M1/M2 paradigm is
often criticized as too simplistic (Ransohoff, 2016). However,
this paradigm conveniently reflects the most phenotypically
distant (polar) differentiation states of macrophages, and the
terminology has caught on and is extensively used in research
literature (Ransohoff, 2016; Poltavets et al., 2020).
The main idea is that microglia appears to be more sensitive
to pathogens; these cells activate and secrete “molecular signals”
such as interleukin-1 alpha (IL-1α), TNF-α, and the complement
component subunit 1q (C1q) to trigger reactive astrocytes
(Liu et al., 2020). Astrocytes in turn release NTFs to support
neuronal survival. For instance, Chen et al. (2015) showed that
astrogliosis is neuroprotective as a result of NTFs release from
astrocytes. Neutralization of supernatant GDNF released from
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astroglia significantly reduced neuroprotective effect of astroglia
in a model of inflammation caused by bacterial inflammogen
lipopolysacharide (LPS). Importantly, LPS failed to induce the
synthesis and release of TNF-α and iNOS/NO from highly-
enriched astroglial culture (Chen et al., 2015). This may suggest
that astroglia itself may not have the ability to directly recognize
the innate immune stimuli such as LPS. Instead astrocytes rely on
microglia which recognize inflammogen and trigger the release
of NTFs from astrocytes (BDNF, CNTF, NGF, MANF) in order to
counterbalance collateral damage caused by activated microglia
and neuroinflammation. This process aims to support neuronal
survival (Liddelow et al., 2017; Jha et al., 2019; Pöyhönen et al.,
2019).
Although the vast majority of researchers agree on the
important role of microglia in the development and maintenance
of neuropathic pain in some studies the importance of
astrocytes in this process is stressed. For instance, it was
shown that in vincristine-evoked chemotherapy-induced
neuropathic pain in rats with obvious mechanical allodynia
spinal astrocytes rather than microglia were dramatically
activated. These data suggest that astrocytes can play a key
role in pathophysiology of chemotherapy-induced neuropathic
pain and Astrocyte-Cytokine-NMDAR-neuron pathway may
be one of the mechanisms underlying chemotherapy-induced
neuropathic pain (Ji R.-R. et al., 2013).
To summarize this section, multiple cell types play a role in the
development and maintenance of neuropathic pain (Figure 1).
It is nearly impossible to isolate neuronal or non-neuronal
components playing the leading role in this process. Perhaps
a key strategy in neuropathic pain management should be
focused on the regulation of interactions between glial cells,
including astrocytes and microglia, and neurons (Zhuo et al.,
2011). Thus, understanding of communications between various
cell types playing roles in neuropathic pain is very important
for the development of efficient analgesics (Ji R.-R. et al., 2013;
Ji et al., 2016). NTFs or their receptors which, as described
in the following sections, are able to influence both neuronal
and non-neuronal cells, may represent valuable targets for
innovative drugs for neuropathic pain management. GFLs and
their receptors (see below) are especially interesting in the context
of neuropathic pain as they are, in contrast to other NTFs, were
shown to restore all types of sensory neurons and to target their
axons into topographically correct regions of spinal cord in a
model of dorsal root crush (Harvey et al., 2010). Extensively
studied approach focused on the disruption of NGF signaling
using monoclonal antibodies or neurotrophin inhibitors is less
attractive in this sense as it is not disease-modifying.
GLIAL CELL LINE-DERIVED
NEUROTROPHIC FACTOR FAMILY
LIGANDS, THEIR RECEPTORS AND
SIGNALING
GFLs include 4 closely related proteins: GDNF, neurturin
(NRTN), artemin (ARTN), and persephin (PSPN) and
a distant recently discovered member, a protein called
Growth/differentiation factor 15 (GDF15). The main receptor
transmitting GFL signals inside neurons is a receptor tyrosine
kinase Rearranged in transfection (RET) (Trupp et al., 1996;
Mahato and Sidorova, 2020b). GFLs do not bind RET directly,
instead they interact with a co-receptor GDNF family receptor
alpha (GFRα) or GDNF family receptor α-like (GFRAL).
GDNF has highest affinity to GFRα1, but can also signal via
GFRα2, NRTN’s preferred receptor is GFRα2, ARTN’s—GFRα3,
PSPN’s—GFRα4. In addition, NRTN, ARNT, and PSPN can
all exert their biological effects via GFRα1. GDF15 binds to
GFRAL and does not seem to have affinity to GFRα co-receptors
(Emmerson et al., 2017; Mullican et al., 2017; Yang et al.,
2017). Formation of a dimeric ligand-co-receptor complex
(stoichiometry 1:2) leads to the recruitment of two monomers of
RET into the compex, autophosphorylation of tyrosine residues
in RET kinase domain and subsequent activation of multiple
signaling cascades and enzymatic pathways important for
cellular survival and functional activity (Airaksinen and Saarma,
2002), such as JAK/Stat, PI3K/Akt, MAPK, JNK, RAC1, VAV2,
PLCγ (Mulligan, 2014; Zhu et al., 2015).
In addition to RET, GFLs in complex with GFRα co-receptors
signal via neural cell adhesion molecule (NCAM) activating
Fyn and FAK protein kinases. This mechanism was shown
to mediate migration of Schwann cells and neurite outgrowth
in hippocampal and cortical neurons (Paratcha et al., 2003).
Also GFLs can activate certain events in the cells via surface
Heparan Sulfate Proteoglycan, Syndecan−3 in the absence of
co-receptors. GFL interaction with Syndecan-3 stimulates Src-
dependent signaling and is important for migration of cortical
GABA-ergic neurons (Bespalov et al., 2011).
EFFECTS OF GLIAL CELL LINE-DERIVED
NEUROTROPHIC FACTOR FAMILY
LIGANDS IN PRIMARY SENSORY
NEURONS
GDNF and ARTN have well-established roles in somatosensory
system. Modulation of their expression levels in the tissues of
experimental animals alters the number of sensory neurons in
DRGs. In GDNF knockout mice the number of sensory neurons
in DRGs is reduced by ∼30% and in mice overexpressing
GDNF—increased by about 30%. In mice overexpressing ARTN
the number of primary sensory neurons is increased by 20%
(reviewed in Ernsberger, 2008). Ablation of GDF15 gene in
mice also led to the 20% decrease in the number of primary
sensory neurons in DRGs (Strelau et al., 2009). However, NRTN
overexpression in the skin was not accompanied by the changes
in overall number of sensory neurons in DRGs (Wang et al.,
2013).
DRG neurons of mammalians express RET and GFRα
co-receptors. Expression of RET and GFRα coreceptors in
primary sensory neurons highly, but not completely overlap. The
number of DRG neurons expressing GFL receptors depends on
developmental stage and increases after birth. Approximately
60% of adult rodent DRG neurons in normal conditions are RET
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positive, upto 50% are GFRα1-positive, up to 33% are GFRα2–
positive and upto 40% are GFRα3–positive (Ernsberger, 2008;
Mahato and Sidorova, 2020a). In human DRGs higher number
of neurons express RET (80%) and GFRα2 (52%) (Josephson
et al., 2001). Expression of GFL receptor complex components
in primary sensory neurons can change after lesion. In rodents
the number of RET-positive and GFRα3-positive cells in DRGs
increases, but the number of GFRα2-positive cells decreases.
The neurons which in normal conditions express GFRα2 upon
injury are converted into GFRα3-positive cells (Wang et al., 2011;
Mahato and Sidorova, 2020a).
The data regarding GFLs expression in DRG neurons are
somewhat controversial. According to the recent review of
Merighi (2018) small portion of DRG neurons (<10%) expresses
GDNF protein as shown by immunological methods. At the
same time transcriptomics studies failed to detect GDNF mRNA
in DRGs. We also failed to reliably detect mRNA of GFLs in
uninjured rodent DRGs by RT-qPCR method. This discrepancy
can be explained by either contribution of non-transcriptional
mechanisms in the GFL protein synthesis or unspecific binding
of GDNF antibodies. Indeed, in our hands many commercially
available GDNF antibodies produced non-specific staining in the
tissues of experimental animals. Interestingly, in DRGs GDNF-
immunoreactive neurons were also CGRP-immunoreactive,
while RET andGFRα co-receptors expressing neurons aremainly
IB4-positive (Merighi, 2018).
In the spinal cord GFL receptors are expressed in lamina
IId which receives and integrates input mainly from C-fibers
(Merighi, 2018). Anatomic localization of GFL receptors in
the spinal cord supports the important role of GFLs in pain
signal transmission.
The GDNF co-receptor (GFRα1) can be released from the
surface of neurons and glia in its soluble form. In this way GFLs
can interact with corresponding GFRαs in solution and then with
RET on cell surface thus activating cells expressing only RET
(Airaksinen and Saarma, 2002; Jmaeff et al., 2020b).
The effects of GFLs in primary sensory neurons in the
context of neuropathic pain are complex. From one hand they
support the survival and repair sensory neurons, eliminating
lesion and consequently the cause of neuropathic pain. Therefore,
these proteins and their receptors serve as attractive therapeutic
targets for disease-modifying treatments of NP. However, GFLs
also stimulate the expression of various proteins increasing
excitability of neuronal cells, such as ion channel subunits
and thus potentiate signal appearing as a result of nociceptive
stimulation. We recently reviewed effects of GFLs in different
chronic pain models in detail. In general, in neuropathic pain
GFLs given intermittently are mainly analgesic, however they
may be pronociceptive in inflammatory pain states and in healthy
animals (Mahato and Sidorova, 2020a).
Interestingly, certain pronociceptive effects of GFLs can be
mediated by sensory neurons expressing only GFL co-receptors
in the absence of RET. In particular, in DRGs cold stimulation
activates TRPM8-positive neurons expressing GFRα3, but
lacking RET (Lippoldt et al., 2013, 2016). This means that in
certain subpopulations of primary sensory neurons GFLs signal
via other known (e.g., NCAM) or yet to be identified receptor(s).
GFRα co-receptors are also expressed in non-neuronal cells,
which can influence nociceptive response to stimulation. This
suggests that some of pronociceptive effects of GFLs can be
mediated via RET independent mechanisms and highlights the
possibilities to improve tolerability of GFL-based therapeutics, by
development of variants selectively targeting RET.
EFFECTS OF GLIAL CELL LINE-DERIVED
NEUROTROPHIC FACTOR FAMILY
LIGANDS IN GLIAL CELLS
Due to the well-established neurotrophic activity of GFLs they
have been mainly studied for the ability to protect neurons from
neurotoxic or mechanical lesion (Gash et al., 1996; Boucher
et al., 2000; Airaksinen and Saarma, 2002; Gardell et al., 2003;
Sidorova et al., 2017; Mahato and Sidorova, 2020a). However,
several studies demonstrated the ability of these proteins to affect
non-neuronal cells involved in inflammatory process which is
developing upon the injury occurring in somatosensory system.
GFLs receptors GFRα1 and RET are expressed in glial cells and
can be upregulated under pathological conditions. GDNF itself
is widespreadly expressed in both neuronal and non-neuronal
cells in the developing human fetal brain starting from 7 weeks
of gestation (Koo and Choi, 2001).
Primary rat glial cells cultures mainly composed of astrocytes
express at least GDNF, NRTN, GFRα1, and GFRα2 (Rémy et al.,
2001). Moreover, GFRα1 and GDNF are released by the reactive
astrocytes (Bresjanac and Antauer, 2000; Marco et al., 2002).
Microglial cells express GFRα1 and RET (Honda et al., 1999;
Boscia et al., 2009, 2013; Rickert et al., 2014) and also synthesize
and secrete GDNF (Matsushita et al., 2008). GFLs have proven
effects in these cells (Rocha et al., 2012; Rickert et al., 2014).
For example, Rickert et al. (2014) showed that GDNF, NRTN,
ARTN and PSPN are able to reduce nitric oxide production
by microglial cells and decrease mRNA levels of IL-1β, TNF-
α, IL-6, and Cox-2 in these cells. Thus, this study proves that
at least in vitro GFL members interfere with the synthesis and
release of pro-inflammatory and neurotoxic molecules generated
by the activated microglia (Rickert et al., 2014) implying active
involvement of GFL in quenching neuroinflammation. Rocha
et al. (2012) in the culture of midbrain microglia stimulated
with zymosan A, demonstrated that astrocytic GDNF is able
to inhibit the activation of microglia, namely, its phagocytic
activity and the production of reactive oxygen species, since
both parameters were greatly reduced in cells incubated with
an astrocyte conditioned medium. To evaluate the nature of the
soluble mediators astrocyte conditioned media was treated with
specific antibodies against GDNF, CDNF, and BDNF in order
to specifically sequester each of the above-mentioned NTFs and
thus revert the changes induced by their presence (Rocha et al.,
2012).
Chang et al. (2006) showed that GDNF has a positive
regulatory effect on functional activity of primary rat microglia
increasing the enzymatic activity of superoxide dismutase (SOD),
expression of surface antigen intercellular adhesion molecule-
1 (ICAM-1), the production of the integrin alpha5 subunit,
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and the phagocytic capability (Chang et al., 2006). GDNF was
also able to support the survival of primary microglia in vitro
(Salimi et al., 2003).
Matsushita et al. (2008) investigated the ability of microglia
to produce and secrete GDNF in vitro. Secretion, but not
synthesis of GDNF, was strongly suppressed in LPS-stimulated
microglia. Because the stimulation of microglia with LPS led
to the accumulation of GDNF in the cells as well as their
morphological activation, it is plausible to hypothesize that the
deposition of GDNF in the cells may be necessary for the process
of microglial activation. The suppression of GDNF secretion
was mediated by protein kinase C alpha (PKCα) and mitogen-
activated protein kinases (MAPK) signaling cascades (Matsushita
et al., 2008).
Apart from the direct effects on microglial and astroglial
cells, GDNF modulates the relationships between microglia and
astrocytes and astrocytes and neurons. Microglia-derived GDNF
protected astrocytes against in vitro ischemia-induced damage
(deprivation of glucose, oxygen, and serum) (Lee et al., 2004;
Lu et al., 2005). GDNF inhibited the apoptosis of the ischemic
astrocytes via upregulation of expression of extracellular signal-
regulated kinase (ERK1/2) and nuclear factor-kappa B (NF-kB)
pathways in a caspase 3-independent manner (Chu et al., 2008;
Zlotnik and Spittau, 2014).
GDNF released from astroglia protected neurons from
inflammation-induced neurotoxic damage, showing that at least
in this condition the astrogliosis is principally neuroprotective
(Chen et al., 2015).
In deafferentation pain model the bone marrowmesenchymal
stem cells (BMSC) inhibited neuroinflammation by transforming
microglial destructive M1 phenotype into regenerative M2
phenotype, thus alleviating pain. This process likely occurred
via GDNF-induced suppression of NF-κB and activation of
PI3K/AKT signaling pathways (Zhong et al., 2020).
In addition to neurons and glia GDNF can also influence non-
nervous system cells. Endothelial cells may also express GFRα1
and GFRα2 as it was shown for the cells composing blood-retinal
and blood brain barriers (Igarashi et al., 1999, 2000). GDNF also
enhanced the phagocytic activity of the macrophages via GFRα1
in a Ret-independent manner (Hashimoto et al., 2005).
A recent review by Duarte Azevedo et al. (2020) compiled
information regarding GDNF and its production in health
and disease in the central nervous system. The authors
conclude that neuroinflammation induces GDNF expression
in activated astrocytes and microglia, infiltrating macrophages,
nestin-positive reactive astrocytes, and neurons/glia (NG2)-
positive microglia-like cells (Duarte Azevedo et al., 2020). In
addition, RET and GFRα1 expression in glia is upregulated
thus, GDNF can produce direct effects in these cells
(Duarte Azevedo et al., 2020).
One important direction of pain research is detecting sex
differences, deciphering the mechanisms of these differences
in the development and maintenance of neuropathic pain and
the analysis of sex difference in response to analgesics. Routine
animal studies have generally been conducted in males mainly
to avoid the influence from cyclic sex hormone fluctuations
occurring in females and thus to reduce animal usage and
overcome funding limitations. However, there are numerous
reports in literature indicating that neuropathic pain is more
common in women. Moreover, women tend to be less responsive
to analgesics. While the scope of this review does not allow us to
go deep into this topic, a nice summary of the available data and
hypotheses explaining sex differences in pain perception can be
found in the reviews and editorials authored and co-authored by
J. Mogil (Craft et al., 2004; Mogil and Bailey, 2010; Mogil, 2016,
2020; Rosen et al., 2017).
Given to the fact of sex-bias in the recent years the number
of animal studies deciphering sex differences in pain has
substantially increased (Bartley and Fillingim, 2013). Despite
of the efforts final conclusions on the mechanisms of sex-
specific differences in pain are yet to be reached. In experimental
animals both sexes show identical morphological reactivity
of microglia (i.e., microgliosis) after nerve injury. However,
microglia inhibitors are anti-nociceptive only in male rodents
(Sorge et al., 2015). The sex-specific differences in GFLs and GFL
receptors expression are not clearly described. Lopes et al. (2017)
in a recent study conducted using RNA-seqmethodology failed to
detect clear sex-bias in the expression of neuronal or glial markers
in somatosensory system, but reported a difference in expression
of peripheral immune cell markers (Lopes et al., 2017). Further
studies of sex difference in pain are essential to understand the
mechanisms and develop efficient analgesics.
TARGETING GFL RECEPTORS WITH
SMALL MOLECULES OR PROTEINS
DOWNREGULATE GLIAL MARKER
EXPRESSION IN SURGERY AND
DIABETES-INDUCED NEUROPATHY
In line with the literature described above, our preliminary
experimental results also support the notion that GFLs or
compounds targeting GDNF receptor RET (Bespalov et al., 2016;
Sidorova et al., 2017; Viisanen et al., 2020) can reduce the
expression of satellite glia marker in sensory ganglia of animals
with surgery or diabetes-induced neuropathy.We developed RET
agonists (compounds BT18 and BT44) and showed that they,
similarly to GDNF and ARTN, activate RET and downstream
signaling in immortalized cells. In surgery- and diabetes-induced
models of neuropathic pain in rats both of these compounds
alleviated mechanical hypersensitivity. They also protected and
restored expression of sensory neuron markers in DRGs in vivo
(Bespalov et al., 2016; Sidorova et al., 2017; Viisanen et al., 2020).
We evaluated the expression of glial marker Ionized Calcium-
Binding Adapter Molecule 1 (IBA1) in DRGs of rats with
neuropathies after the treatment with ARTN or RET agonists
(experimental design and sample collection procedures, as well
as the effects of compound on pain threshold and on neurons
are described in details elsewhere (Sidorova et al., 2017; Viisanen
et al., 2020) using immunohistochemistry method described in
details in Jokinen et al. (2018). Briefly, 5 micrometers sections
of DRGs were probed with antibodies against IBA1 (1:1000, Cat.
No. 019-19741, Wako, Richmond, VA, USA). For visualization
of the bound antibodies we used a VECTASTAIN ABC HRP
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FIGURE 2 | Expression of IBA-1 in dorsal root ganglia (DRG) of animals with surgery (spinal nerve ligation, A–C) or diabetes-induced neuropathy (D,E). (A) Expression
of IBA1 (area) in DRGs which spinal nerve was ligated upon the treatment with vehicle (VEH), BT18 (the first generation RET agonist, subcutaneously at the dose 25
mg/kg every other day for 12 days, started 1 h after the lesion), and ARTN (at the dose 0, 5 mg/kg every other day for 12 days, started 1 h after the lesion), n = 3 per
group. (B) Expression of IBA1 in DRGs on the unligated side of the body (healthy), the treatments and doses are the same as in (A), n = 3 per group. (C) Expression
of IBA1 (area) in DRGs which spinal nerve was ligated upon the treatment with vehicle (VEH) or BT44 (the second generation RET agonist, subcutaneously at the dose
12.5 mg/kg every other day for 12 days, started 2 days after the lesion) or on unleasoned side (UNL), n = 3–4 per group. (D) Expression of IBA1 (area) in DRGs of
healthy animals (healthy) or animals with diabetes-induced neuropathy treated subcutaneously with vehicle (DM) or BT44 (at the dose 5 mg/kg every other day for 3
weeks started on the day of lesion), n = 4–5 per group. (E) As in (D), but the number of cells is calculated, n = 5 per group, *p < 0.05, **p < 0.01 by ANOVA and
post-hoc test, #p < 0.05 by post-hoc test (ANOVA p = 0.059).
Kit according to the manufacturer’s instructions. Sections were
imaged with help of 3DHISTECH Scanner (3DHISTECH Ltd,
Budapest, Hungary). Image analysis (the number of IBA1-
positive cells and the area covered by IBA1-positive staining) was
performed with Matlab R2014b software (Mathworks, Natick,
MA, USA) using a custom script (Penttinen et al., 2016; Jokinen
et al., 2018). The data collected from two non-consecutive
sections per animal were averaged and used for statistical analysis
by ANOVA with Dunnett’s post-hoc test. Each group included
3–5 animals.
In our pilot experiments we consistently saw a decrease in
the area and/or number of IBA1-positive cells in DRGs of
animals with experimental neuropathies treated with ARTN or
RET agonists compared to the values seen in DRGs of animals
treated with vehicle (Figure 2). In some of these experiments this
reduction was statistically significant, while in others we saw only
a trend to a decrease. In ipsilateral DRGs of rats with spinal nerve
ligation-induced neuropathy the area of IBA1-positive staining
was ∼3 times higher compared to that in contralateral DRGs.
The treatment of rats with spinal nerve ligation (SNL) with
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either BT18 or ARTN every other day except weekends for a
12-days period starting 1 h after the surgery (Bespalov et al.,
2016) resulted in a statistically significant decrease in the area
covered by IBA1-positive signal in ipsilateral DRGs (Figure 2A).
At the same time in contralateral DRGs statistically significant
changes in the expression of studied marker were not detected
(Figure 2B). In another experiment we also saw a statistically
significant increase in IBA1 expression in ipsilateral DRGs after
spinal nerve ligation (Viisanen et al., 2020). The treatment with
a RET agonist, compound BT44, which started 2 days after
the surgery when neuropathy was already established, partially
normalized this change, although statistically significant decrease
was not seen (Figure 2D). In rats with diabetic neuropathy
induced by streptozotocin (STZ) administration (Viisanen et al.,
2020) BT44 treatment resulted in the decrease in the area
(Figure 2D), but did not influence in the number of IBA1-
positive cells (Figure 2E). This result is fully in line with recently
published data of Ciglieri et al. (2020). These authors observed
cytoarchitectonic changes related to glia-neuronal interactions in
DRGs upon the treatment with STZ, while the overall number of
SGC remained largely unaffected. In particular, STZ differentially
affected the expression of SGC marker surrounding different
subpopulations of DRG neurons and disturbed glia-neuron and
neuron-neuron contacts in this tissue (Ciglieri et al., 2020).
To summarize, our data taken together are in line with
published observations on the ability of GFLs to downregulate
activation of glial cells and mitigate neuroinflammation
described above. While clinical translation of GFL proteins
is complicated, small molecules targeting their receptors
(Sidorova et al., 2017; Jmaeff et al., 2020a,b; Viisanen et al.,
2020) may be a better alternative for use in humans to treat
neuropathic pain. Previously we showed that RET agonists
are neuroprotective/neurorestorative in animal models of
neuropathic pain (Sidorova et al., 2017; Viisanen et al., 2020).
Here, we provide evidence that these small molecules can also
downregulate glial cells activation being thus dual action agents.
SUMMARY AND CONCLUSIONS
GFLs attracted a lot of attention of scientific community
as potential disease-modifying treatments against
neurodegeneration due to their well-known neuroprotective
effects in various neuronal populations. In the present paper we
reviewed published and provided our own data showing that
GFLs can also modulate neuroinflammation which accompanies
and exaggerates neurodegeneration. Based on the available
data regarding the expression of GFL receptors in various
cell types it is reasonable to conclude that these proteins may
directly influencing immune, endothelial and glial cells, and also
regulate their interactions. The ability of GFLs to influence both
neuronal and glial cells further increases their attractiveness
as targets for the development of novel treatments against
neurodegeneration. While the use of GFL proteins in humans
is complicated, small molecules that target GFL receptors
may serve as better alternatives for clinical translation. We
developed compounds that target the main GFL receptor RET
and possess both neuroprotective properties and an ability to
suppress glial activation in sensory system. Further optimization
of these compounds can result in a disease-modifying drug
normalizing the function of all cell types involved in the process
of pain chronization, which will revolutionize neuropathic
pain management.
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